Executive summary Stroke is the second leading cause of death worldwide. The burden of
disability after a stroke is also large, and is increasing at a faster pace in low-income and …

Background: There are no evidence-based recommendations on the optimal time point to
initiate non–vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in …

Background Residual risk of ischemic stroke despite anticoagulation in patients with atrial
fibrillation (AF) represents a significant clinical issue that remains unaddressed. We aimed to …

Background For patients with atrial fibrillation and a prior stroke or transient ischemic attack
(TIA), the risk-benefit of direct oral anticoagulants (DOACs) compared to alternative …

Importance The Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial
found that approximately 1 in 8 patients with recent ischemic stroke attributed to large-or …

Background: The optimal timing of initiating or resuming anticoagulation after acute ischemic
stroke (AIS) or transient ischemic attack (TIA) in patients with atrial fibrillation (AF) is …

Background This propensity-score matched study investigated clinical outcomes associated
with left atrial appendage occlusion (LAAO) versus direct oral anticoagulation (DOAC) in …

Objective Patent foramen ovale (PFO) is often found in stroke patients with determined
etiologies. PFO may be the actual cause of stroke in some of them. We determined whether …

Patients who have ischaemic stroke or a transient ischaemic attack have a high risk of
recurrent ischaemic stroke. This risk is highest in the first few days after the primary …

Previous studies have rarely investigated the role of non-vitamin K oral anticoagulants
(NOAC) and warfarin in the secondary prevention of ischemic stroke patients with …